Ruijin Hospital (上海交通大学医学院附属瑞金医院), affiliated with Shanghai Jiao Tong University School of Medicine, has been ranked in China’s top-tier hospitals for over a decade. Founded in 1907, it carries over a century of clinical tradition combined with world-class CAR-T cell therapy, haematology, and endocrinology. Its International Medical Center (IMC) is one of Shanghai’s most experienced units for international patient coordination. For the right case, it may be a suitable option for top-tier national expertise in CAR-T and haematology — but whether it’s appropriate for your situation depends on your diagnosis and objectives. China Care helps you work that out before you travel, then provides bilingual escort throughout your stay.
Ruijin Hospital (上海交通大学医学院附属瑞金医院) was founded in 1907 by French missionaries as St Marie Hospital in the French Concession of Shanghai. Today, as an affiliate of Shanghai Jiao Tong University School of Medicine, it consistently ranks in China’s top-tier hospitals and serves as a national reference center for haematology, endocrinology, and cardiovascular medicine.
The hospital’s haematology department is one of China’s most respected, with deep expertise in NMPA-approved CAR-T protocols, bone marrow transplantation for lymphoma, leukaemia, and multiple myeloma, and complex haematological malignancies. Ruijin’s haematology team has been involved in landmark Chinese clinical trials for novel haematological therapies and is a reference center for difficult or relapsed cases referred from across China.
The International Medical Center (IMC) at Ruijin is one of Shanghai’s most experienced for international patient coordination. Staff are well-versed in the documentation required for S2 medical visa applications and have supported hundreds of international patients through the process. China Care works directly with the IMC to coordinate case referrals, ensure smooth admissions, and manage documentation for both treatment and visa purposes.
Ruijin’s International Medical Center has processed hundreds of medical visa invitation letters for international patients seeking haematology, oncology, and endocrinology care. The IMC team understands exactly what documentation Chinese embassies require. China Care coordinates directly with the IMC to ensure your visa support documents are complete and consistent, minimising the risk of application delays or rejections.
Ruijin’s haematology department runs NMPA-approved CAR-T cell therapy protocols for B-cell lymphoma, acute lymphoblastic leukaemia, and multiple myeloma. The bone marrow transplant unit is one of Shanghai’s most active, with strong outcomes in allogeneic transplantation for AML, ALL, and lymphoma. Multiple active haematology trials provide access to investigational agents for relapsed and refractory cases.
Ruijin is one of China’s leading centers for complex endocrinology — type 1 diabetes, type 2 diabetes with complications, thyroid disease (Graves’, Hashimoto’s, thyroid cancer), adrenal disorders, pituitary disease, and metabolic conditions. Its endocrinology department has one of the longest patient outcome databases in China and is involved in major national diabetes research programmes.
Finding a hospital's name is easy. Knowing whether it's actually the right one for your situation is much harder — that's where China Care helps.
Most international patients researching Ruijin Hospital are unsure whether it's genuinely the right fit for their case, or whether another hospital might serve them better. China Care helps you answer questions like:
Ruijin Hospital covers more than 40 clinical departments. Below are those most frequently accessed by international patients through China Care.
Finding a hospital is the easy part. Understanding whether it's the right one for your situation is harder — China Care guides you through that, from initial guidance through to on-the-ground support in Shanghai.
Share your medical records, test results, and diagnosis. For haematology cases, include bone marrow biopsy, molecular markers, prior treatment history, and CD19/BCMA expression results for CAR-T eligibility assessment. For endocrinology cases, include HbA1c history, hormone panels, and any relevant imaging. China Care prepares a bilingual case summary for the relevant Ruijin department within 1–2 working days.
1–2 daysChina Care registers your case with Ruijin Hospital's IMC, translates your medical records and referral documents, and confirms your appointment date, department, and specialist before you arrange your travel — all coordinated in English on your behalf. This is a fixed-fee service, agreed with you upfront. Already in China? Skip this step — China Care can arrange direct escort and interpretation for your own visit instead.
Hospital Access · fixed fee · confirmed appointmentWith your appointment confirmed, you travel to Shanghai for your own in-person consultation at Ruijin. The specialist reviews your case in person, confirms the treatment plan, and issues a formal cost estimate — this step cannot be completed remotely at a public hospital. China Care’s bilingual coordinator accompanies you throughout. For CAR-T and BMT cases, the haematology team will confirm eligibility at this appointment.
in-person consultation · treatment plan & cost estimate issuedChina Care coordinates your hospital admission through the IMC. For CAR-T therapy, leukapheresis (T-cell collection) occurs first, followed by a manufacturing period of approximately 7–21 days, then lymphodepletion and CAR-T infusion. China Care coordinates accommodation and logistics during the manufacturing wait period. For BMT cases, conditioning begins after admission. For endocrinology cases, outpatient treatment allows flexible scheduling.
All treatment fees are paid directly to the hospital in Chinese yuan (RMB). Accepted payment methods vary by hospital — China Care will confirm with Ruijin before you travel. A deposit is required at admission; the balance is settled before discharge. China Care does not collect or handle medical payments.
IMC admission · payment direct to hospitalFull discharge documentation is provided including treatment summary, laboratory results, and follow-up monitoring plan. For CAR-T and BMT patients, a detailed post-treatment monitoring schedule is established before discharge. For endocrinology patients, ongoing management guidance including medication protocols is provided in written form for your home physician. China Care ensures all documentation is prepared in a format compatible with your home doctor.
bilingual documentation · monitoring plan · post-discharge supportWhichever stage you're at, China Care's role is the same: help you make an informed decision, not just a booking.
We'll help you understand whether Ruijin Hospital — or another hospital in China — may be a better option for your situation.
China Care coordinates your case with Ruijin Hospital’s International Medical Center. Treatment costs are quoted directly by the hospital. We never add to or mark up the hospital’s quoted treatment cost.
Hospital profile note: This profile is general reference information. China Care does not endorse or guarantee a particular hospital, treatment, appointment, clinical decision, or outcome. Current services, requirements, language support, availability, and clinical suitability should be confirmed directly with the hospital.